AP26113...
Hey guys,
Amid all this share price turmoil, I'm wondering if anyone has a strong opinion on the approval timeline for 113.
Assuming that it gets thru phase 1 with results that are roughly comparable to preclinicals, and seeing as it will be addressing an unmet need regarding ALK mutations, should we assume that it will also be eligible for fast-tracking (like 534), meaning we could look for another pivital trial initiation in early 2012?
Seems like this has fortunately become ariad's MO of late with orphan drug status(rida) and fast tracking(534), and, like dougheuring mentioned, should precipitate a DNDN-type eruption when these hedge fund guys finally decide to look up from their bunkers and shed the stereotype of ariad as an all science and no product company that materialized over the last decade. I know how they feel b/c I often had the same feeling. Because of this,(and their on again, off again attitude toward risk assets like biotech) it seems likely they're not really listening yet.
However, as has also been noted, it should be a quick and volatile transformation when they do.
Anyway I wanted to say that I really like the look of this new board, and I'd like to hear what others think about the 113 timeline. Another important piece of the puzzle.
Best all,
bw
